Core Viewpoint - Revvity, Inc. is a life sciences and diagnostics company with a market cap of $11.1 billion, providing essential tools for genetic screening and infectious disease testing [1] Financial Performance - Analysts anticipate Revvity to report an adjusted earnings of $1.54 per share for the fourth quarter, reflecting an 8.5% increase from $1.42 per share in the same quarter last year [2] - For fiscal 2025, adjusted EPS is expected to be $4.91, slightly up from $4.90 in 2024, with a projected 8.2% annual increase to $5.31 per share in fiscal 2026 [3] Stock Performance - RVTY stock has decreased by 12.4% over the past 52 weeks, underperforming compared to the Healthcare Select Sector SPDR Fund's 13% increase and the S&P 500 Index's 16.9% gain [4] Growth and Profitability Challenges - Revvity has experienced weak underlying growth with constant-currency revenue growth averaging only 2% over the last two years, indicating soft demand [5] - Profitability has declined, with adjusted operating margin decreasing by over 9 percentage points in the past five years due to rising costs and limited operating leverage [5] - Financial performance has deteriorated, with both revenue and EPS declining annually over the past five years, leading to cautious investor sentiment [5]

Company Overview - Revvity, Inc. (RVTY) has a market capitalization of $10 billion and is a global provider of health sciences solutions, technologies, and services, offering a wide range of products including instruments, reagents, informatics, software, imaging technologies, DNA sequencing services, and diagnostic platforms for genetic and infectious disease testing [1][2] Stock Performance - Revvity's shares have decreased by 33.1% from their 52-week high of $129.50 and have fallen 8.8% over the past three months, underperforming the Health Care Select Sector SPDR Fund (XLV), which gained 3.7% during the same period [3] - Year-to-date, RVTY stock is down 22.4%, while XLV has experienced a marginal drop. Over the past 52 weeks, Revvity shares have decreased by 29.1%, compared to XLV's 11.2% decline [4] Financial Forecast - On July 28, Revvity's shares fell 8.3% after the company revised its full-year adjusted profit forecast to $4.85 to $4.95 per share, citing weaker demand in China, where diagnostic product sales declined by double digits in Q2 2025 due to new reimbursement policies [5] - The company now expects diagnostics sales growth to be in the low single digits, down from an earlier forecast of mid-single digits [6] Analyst Sentiment - Despite the weak stock performance, analysts maintain a moderately optimistic outlook for Revvity, with a consensus rating of "Moderate Buy" from 18 analysts and a mean price target of $114.62, representing a 33.7% premium to current levels [7]